Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This health technology assessment (HTA) will inform decisions regarding the accuracy, and clinical and cost-effectiveness of point-of-care (POC) International Normalized Ratio (INR) compared with standard laboratory testing, and compared with other POC INR devices. A systematic review to evaluate the clinical effectiveness of POC INR compared with laboratory methods, and other POC INR devices, followed by a review of economic evaluation studies will be conducted. CADTH will also conduct a primary economic analysis of the cost-effectiveness of POC INR from a Canadian perspective.
Contents
Suggested citation:
Canadian Agency for Drugs and Technologies in Health. Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy – Project Protocol [Internet]. Ottawa: The Agency; 2013 Jul. (CADTH Optimal Use Report; vol.3 no.1a). [cited yyyy mmm dd]. Available from: http://www.cadth.ca/media/pdf/Point-of-care_INR_Protocol_e.pdf
This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.
The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
- NLM CatalogRelated NLM Catalog Entries
- Review Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy: Systematic Review and Economic Analysis[ 2014]Review Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy: Systematic Review and Economic Analysis. 2014 Jul
- Review Guidance on the Use of Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy[ 2014]Review Guidance on the Use of Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy. 2014 Jul
- International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing.[Semin Thromb Hemost. 2015]International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing.Bonar R, Mohammed S, Favaloro EJ. Semin Thromb Hemost. 2015 Apr; 41(3):279-86. Epub 2015 Apr 3.
- Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.[Ann Pharmacother. 2013]Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.Baruch L, Sherman O. Ann Pharmacother. 2013 Sep; 47(9):1210-2.
- An analysis of discrepancy between point-of-care and central laboratory international normalized ratio testing in ED patients with cerebrovascular disease.[Am J Emerg Med. 2012]An analysis of discrepancy between point-of-care and central laboratory international normalized ratio testing in ED patients with cerebrovascular disease.Nanduri S, Tayal AH, Hegde GG, Shang J, Venkat A. Am J Emerg Med. 2012 Nov; 30(9):2025-9. Epub 2012 Jul 12.
- Point-of-Care Testing of International Normalized Ratio for Patients on Oral Ant...Point-of-Care Testing of International Normalized Ratio for Patients on Oral Anticoagulant Therapy – Project Protocol
- Hordeinae granule-bound starch synthase I (GBSSI) gene, exons 9, 11 through 14, ...Hordeinae granule-bound starch synthase I (GBSSI) gene, exons 9, 11 through 14, and partial cds.PopSet: 161789746PopSet
- BioProject Links for Nucleotide (Select 552607948) (1)BioProject
- Pseudomonas aeruginosa BL13Pseudomonas aeruginosa BL13PseudomonasBioProject
- Taxonomy Links for Nucleotide (Select 552617767) (1)Taxonomy
Your browsing activity is empty.
Activity recording is turned off.
See more...